Marty Mangold

Reprise Biomedical

Reprise Biomedical, Inc. is focused on the development and commercialization of biological medical devices which offer advanced solutions for healing. Reprise was established as a spin-off from Miromatrix Medical Inc. in July 2019 and took ownership of the manufacturing, marketing, and distribution for two commercially available products, MiroDerm biologic wound matrix and MiroFlex biologic matrix for soft tissue reinforcement. The company is committed to innovation using our proprietary perfusion decellularization technology to develop new medical devices which address unmet surgical needs for healing. Our newest product, Miro3D wound matrix, is an example of that commitment. Miro3D broadens our wound management portfolio by offering a unique three-dimensional solution for deep and tunneling wounds.